Microbiome and pharmacotherapy in patients with gastrointestinal disorders
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F23%3A00134642" target="_blank" >RIV/00216224:14310/23:00134642 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Microbiome and pharmacotherapy in patients with gastrointestinal disorders
Original language description
Background: Etiopathogenesis of gastrointestinal disorders (GDs), such as gastroesophageal reflux disease (GERD) and its complications, pancreatic cancer (PANC), and colorectal adenocarcinoma (CRC) is multifactorial; risk factors for disease development and/or progression include external factors, dysbiosis of host microbiota, genetic predisposition, and responsiveness to therapy. Objectives: The main aim of the dissertation project is to identify potential markers at the level of the host microbiome. Methods: Human and microbial DNA will be isolated from blood and biopsies from the digestive tract. Microbial DNA will be analyzed by 16S rRNA amplicon sequencing and quantified by multiplex qPCR method. Outcomes: Paired comparison of bacteriomes between healthy and pathological parts of the digestive tract will be performed to identify potentially risky host bacteriome profiles.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30101 - Human genetics
Result continuities
Project
<a href="/en/project/NU20-03-00126" target="_blank" >NU20-03-00126: Host microbiome in relation to Barrett´s esophagus and esophageal adenocarcinoma development</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů